Category | Total (n = 792) |
---|---|
Type of journal, n (%) | |
 − Cancer | 739 (93.3) |
 − General medical | 53 (6.7) |
Journal impact factor, median [Q1–Q3] | 5.3 [4.8–16.4] |
Study design | |
 − Systematic review/meta-analysis | 86 (10.9) |
 − Randomized controlled trial | 246 (31.1) |
 − Phase I/II, non-randomized trial | 113 (14.3) |
 − Observational study | 347 (43.8) |
Cancer type by organ, n (%) | |
 − Digestive system | 168 (21.2) |
 − Breast | 135 (17.0) |
 − Lungs | 82 (10.4) |
 − Blood | 71 (8.9) |
 − Prostate | 53 (6.7) |
 − Female reproductive organ | 44 (5.6) |
 − Others | 239 (30.2) |
Type of cancer treatment, n (%) | |
 − Chemotherapy | 212 (26.7) |
 − Targeted therapy | 88 (11.1) |
 − Radiotherapy | 69 (8.7) |
 − Surgery | 44 (5.5) |
 − Hormone therapy | 28 (3.5) |
 − Immunotherapy | 4 (0.5) |
 − Supportive care | 197 (25.0) |
 − Others | 150 (19.0) |
Sample size, median [Q1–Q3]a | 181.0 [48.5–1010.5] |
Type of abstract conclusion | |
 − In favour of study treatment | 523 (66.0) |
 − Not in favour of study treatment | 269 (34.0) |
Funding source, n (%) | |
 − Non-profit | 418 (52.8) |
 − Profitb | 268 (33.8) |
 − Not reported | 106 (13.4) |
Altmetric score, median [Q1–Q3] | 2.0 [0.0–8.0] |
Open access | |
 − Yes | 462(58) |
 − No | 330(42) |
Press-release | |
 − Yes | 56(7) |
 − No | 736(93) |